Literature DB >> 24408012

FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis.

Ou Huang1, Min Jiang, Xi Zhang, Xiaosong Chen, Jiayi Wu, Kunwei Shen.   

Abstract

Many studies were published to assess the association between FASLG T844C polymorphism and susceptibility to breast cancer, but the data were controversial. A meta-analysis was performed to assess the association comprehensively. We performed a comprehensive search in PubMed, Embase, and Web of Science to find eligible studies. Six studies with a total of 6,784 participants were finally included into the meta-analysis. There were a total of 3,382 cases with breast cancer and 3,402 controls in those six studies. Odds ratio (OR) with 95 % confidence interval (95 %CI) was used to evaluate the association. Overall, there was an obvious association between FASLG T844C polymorphism and breast cancer under all four contrast models (for C versus T: OR = 1.26, 95 %CI 1.05-1.50, P OR = 0.011; for CC versus TT: OR = 1.42, 95 %CI 1.11-1.81, P OR = 0.005; for CC versus TT/TC: OR = 1.41, 95 %CI 1.06-1.88, P OR = 0.019; for CC/TC versus TT: OR = 1.16, 95 %CI 1.01-1.33, P OR = 0.038). In the subgroup analysis by ethnicity, there was an obvious association between FASLG T844C polymorphism and breast cancer in Asians, but there was no obvious association in Caucasians. The meta-analysis suggests that there is an association between FASLG T844C polymorphism and susceptibility to breast cancer, especially in Asians.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24408012     DOI: 10.1007/s13277-013-1145-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.

Authors:  Peter Krippl; Uwe Langsenlehner; Wilfried Renner; Herwig Köppel; Hellmut Samonigg
Journal:  J Natl Cancer Inst       Date:  2004-10-06       Impact factor: 13.506

Review 2.  FASLG polymorphism is associated with cancer risk.

Authors:  Yan Liu; Qian-Jun Wen; You Yin; Xiao-Tong Lu; Shu-Hong Pu; Huai-Ping Tian; Yue-Fen Lou; Yue-Nian Tang; Xin Jiang; Gen-Sheng Lu; Jian Zhang
Journal:  Eur J Cancer       Date:  2009-05-04       Impact factor: 9.162

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 4.  Breast cancer - one term, many entities?

Authors:  Nicholas R Bertos; Morag Park
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

5.  Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.

Authors:  Bailin Zhang; Tong Sun; Liyan Xue; Xiaohong Han; Baoning Zhang; Ning Lu; Yuankai Shi; Wen Tan; Yifeng Zhou; Dan Zhao; Xuemei Zhang; Yongli Guo; Dongxin Lin
Journal:  Carcinogenesis       Date:  2006-12-20       Impact factor: 4.944

6.  A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.

Authors:  Wen-Wei Sung; Yao-Chen Wang; Ya-Wen Cheng; Ming-Ching Lee; Kun-Tu Yeh; Lee Wang; John Wang; Chih-Yi Chen; Huei Lee
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

Review 7.  Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer.

Authors:  Wiem Chaabane; Sırma D User; Mohamed El-Gazzah; Roman Jaksik; Elaheh Sajjadi; Joanna Rzeszowska-Wolny; Marek J Los
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-12-11       Impact factor: 4.291

Review 8.  The role of FasL and Fas in health and disease.

Authors:  Martin Ehrenschwender; Harald Wajant
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

9.  Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk.

Authors:  Ziang Yang; Juping Shen; Zhigang Cao; Biyun Wang
Journal:  Breast Cancer Res Treat       Date:  2013-04-23       Impact factor: 4.872

Review 10.  Pathology of hereditary breast cancer.

Authors:  Petra van der Groep; Elsken van der Wall; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2011-02-19       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.